Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1168
Abstract: Dysphagia is highly prevalent in patients with amyotrophic lateral sclerosis (ALS). Riluzole is a US Food and Drug Administration‐approved treatment for ALS. Riluzole oral film (ROF; Exservan™) contains riluzole in a polymer‐based film matrix. The… read more here.
Keywords: safety; bioavailability; oral film; rof ... See more keywords
Riluzole Oral Suspension: Bioavailability Following Percutaneous Gastrostomy Tube-modeled Administration Versus Direct Oral Administration.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2019.09.016
Abstract: PURPOSE During amyotrophic lateral sclerosis progression, up to 85% of patients develop dysphagia. Riluzole oral suspension 50 mg/10 mL is bioequivalent to riluzole 50-mg film-coated tablets administered orally under fasting conditions. Here, we compare the bioavailability… read more here.
Keywords: administration; tube; riluzole oral; bioavailability ... See more keywords